financetom
Business
financetom
/
Business
/
Update: Eni Shares Fall as Q4 Earnings, Revenue Miss Expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Eni Shares Fall as Q4 Earnings, Revenue Miss Expectations
Feb 27, 2025 7:30 AM

10:05 AM EST, 02/27/2025 (MT Newswires) -- (Updates with stock move in the headline and first paragraph, adds 2025-2028 plan starting in the fourth paragraph.)

Eni (E) shares were falling 1.9% in early Thursday trading after the company reported Q4 earnings and revenue that came in below analysts' estimates.

The company reported Q4 earnings Thursday of 0.07 euros ($0.07) per diluted share, up from 0.05 euros per share a year earlier. Analysts polled by FactSet expected 0.31 euros per share.

Revenue for the quarter ended Dec. 31 was 23.97 billion euros, down from 24.98 billion euros a year earlier. Analysts surveyed by FactSet expected 24.68 billion euros.

Separately, Eni also unveiled its 2025-2028 plan and strategic outlook. Eni Chief Executive Claudio Descalzi said the company expects to grow cash flow from operations, or CFFO, per share at more than 14% per year.

Also, the company's dividend will be "supplemented with a share buy-back plan for an overall payout in the range of 35-40% of CFFO, raised from 30-35% previously, reflecting the strategic, operational and financial advances we have made," Descalzi said.

Descalzi said that, in the event of upside in cash generation, 60% of the additional cash will be distributed to shareholders, which means that for 2025 the proposed dividend will be 1.05 euros per share, up 5% and the share buyback will be initially set at 1.5 billion euros with upside up to 3.5 billion euros.

Eni also said it expects net capital expenditures of 7 billion euros a year between 2025 and 2028, which is "in line with last year despite the significant portfolio activity in 2024 and the effects of cost inflation and the stronger USD."

For 2025, the company expects gross capex below 9 billion euros and pro forma net capex between 6.5 billion euros and 7 billion euros.

Price: 29.33, Change: -0.58, Percent Change: -1.94

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Singular Genomics Gets Acquisition Proposal from Deerfield -- Shares Jump After Hours
Singular Genomics Gets Acquisition Proposal from Deerfield -- Shares Jump After Hours
Sep 13, 2024
04:57 PM EDT, 09/12/2024 (MT Newswires) -- Singular Genomics Systems ( OMIC ) said late Thursday it has received a non-binding proposal from Deerfield Management to buy all of its shares not already owned by Deerfield for $10 per share in cash. Deerfield said in its letter that it plans to invite other major shareholders and existing management to roll...
ITT Completes Acquisition of kSARIA Parent
ITT Completes Acquisition of kSARIA Parent
Sep 13, 2024
04:57 PM EDT, 09/12/2024 (MT Newswires) -- ITT (ITT) said late Thursday it completed the acquisition of kSARIA Parent, a producer of connectivity services for the defense and aerospace end markets, with a funding of a combination of about $460 million term loan and cash on hand. kSARIA generated roughly $175 million in sales during 2023. ...
Ampco-Pittsburgh Unit Gets $8.7 Million Order
Ampco-Pittsburgh Unit Gets $8.7 Million Order
Sep 13, 2024
04:54 PM EDT, 09/12/2024 (MT Newswires) -- Ampco-Pittsburgh ( AP ) said its Air and Liquid Systems unit received an $8.7 million order for a custom air handling project for an undisclosed major pharmaceutical company. The order is expected to ship next year, Ampco-Pittsburgh ( AP ) said Thursday in a statement. Ampco-Pittsburgh ( AP ) shares fell 7.7% in...
Day One Biopharmaceuticals Insider Sold Shares Worth $426,675, According to a Recent SEC Filing
Day One Biopharmaceuticals Insider Sold Shares Worth $426,675, According to a Recent SEC Filing
Sep 13, 2024
04:52 PM EDT, 09/12/2024 (MT Newswires) -- Samuel C. Blackman, Head of R&D, on September 10, 2024, sold 30,000 shares in Day One Biopharmaceuticals ( DAWN ) for $426,675. Following the Form 4 filing with the SEC, Blackman has control over a total of 2,097,535 shares of the company, with 1,097,535 shares held directly and 1,000,000 controlled indirectly. SEC Filing:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved